Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Provides Opportunity For Conditional Approvals, Consumer Groups Say

Executive Summary

Consumer groups are advocating the creation of a "conditional" approval authority for FDA through the reauthorization of the Prescription Drug User Fee Act

You may also be interested in...



Drug R&D Models Will Change Drastically By 2020, PwC Report Predicts

The pharmaceutical industry is about to face a world in which successful companies no longer focus on blockbusters, drugs are approved in stages for an ever widening patient population, and large sales teams have been replaced by advisers, according to a report by PricewaterhouseCooper

Drug R&D Models Will Change Drastically By 2020, PwC Report Predicts

The pharmaceutical industry is about to face a world in which successful companies no longer focus on blockbusters, drugs are approved in stages for an ever widening patient population, and large sales teams have been replaced by advisers, according to a report by PricewaterhouseCooper

PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff

The current round of reauthorization of the Prescription Drug User Fee Act presents a "golden opportunity" to improve FDA's regulation of drug safety, according to the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel